Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 7/20 | 0.46 |
| ▸ | NOS2 | P35228 | 3/20 | 0.43 |
| ▸ | NOS1 | P29475 | 2/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.43 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | ARG1 | P05089 | 1/20 | 0.40 |
| ▸ | ARG2 | P78540 | 1/20 | 0.40 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.38 |
| ▸ | BHMT | Q93088 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL441462 | 1.00 | KIF11 (0.46) | KIF11NOS2NOS1NOS3GRIK1 | |
| SCHEMBL12438549 | 1.00 | KIF11 (0.46) | KIF11NOS2NOS1NOS3GRIK1 | |
| Water SCHEMBL6741667 | 0.98 | KIF11 (0.45) | KIF11NOS2NOS1NOS3GRIK1 | |
| Water SCHEMBL6741664 | 0.98 | KIF11 (0.45) | KIF11NOS2NOS1NOS3GRIK1 | |
| Hydrochloric Acid SCHEMBL4744896 | 0.98 | KIF11 (0.45) | KIF11NOS2NOS1NOS3GRIK1 | |
| L-Homocysteine SCHEMBL15008852 | 0.88 | NOS2 (0.40) | KIF11NOS2NOS1NOS3GRIK1 | |
| SCHEMBL15944812 | 0.83 | NOS2 (0.33) | KIF11NOS2NOS1NOS3GRIK1 | |
| SCHEMBL22280107 | 0.82 | KIF11 (0.42) | KIF11NOS2NOS1NOS3GRIK1 | |
| SCHEMBL11801814 | 0.82 | KIF11 (0.46) | KIF11NOS2NOS1NOS3GRIK1 | |
| SCHEMBL18214470 | 0.82 | KIF11 (0.46) | KIF11NOS2NOS1NOS3GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1830999-A | Process for folding chemically synthesized polypeptides | RMF DICTAGENE SA (CH) | 2006-09-13 | — | — | CN | claimed |
| EP-1679318-A1 | Process for folding chemically synthesized polypeptides | RMF DICTAGENE S.A. (CH) | 2006-07-12 | — | — | EP | claimed |
| EP-1337549-B1 | PROCESS FOR FOLDING CHEMICALLY SYNTHESIZED POLYPEPTIDES | RMF DICTAGENE SA (CH) | 2006-04-05 | — | — | EP | claimed |
| CN-1249078-C | Method for folding chemically synthesized polypeptides | RMF DICTAGENE SA (CH) | 2006-04-05 | — | — | CN | claimed |
| US-20050239162-A1 | Process for folding chemically synthesized polypeptides | RMF DICTAGENE S.A. (CH) | 2005-10-27 | — | — | US | claimed |
| CN-1449406-A | Method for folding chemically synthesized polypeptides | RMF DICTAGENE SA (CH) | 2003-10-15 | — | — | CN | claimed |
| EP-1337549-A2 | PROCESS FOR FOLDING CHEMICALLY SYNTHESIZED POLYPEPTIDES | RMF DICTAGENE S.A. (CH) | 2003-08-27 | — | — | EP | claimed |
| WO-2002050099-A2 | PROCESS FOR FOLDING CHEMICALLY SYNTHESIZED POLYPEPTIDES | RMF DICTAGENE S.A. (CH) | 2002-06-27 | — | — | WO | claimed |
| US-20020082384-A1 | Process for folding chemically synthesized polypeptides | RMF DICTAGENE S.A. (CH) | 2002-06-27 | — | — | US | claimed |
| EP-4737477-A2 | HEPCIDIN MIMETICS FOR TREATMENT OF HEREDITARY HEMOCHROMATOSIS | Protagonist Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4706671-A2 | CONJUGATED HEPCIDIN MIMETICS | Protagonist Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250360187-A1 | HEPCIDIN MIMETICS FOR TREATMENT OF SICKLE CELL DISEASE | PROTAGONIST THERAPEUTICS, INC. (US) | 2025-11-27 | — | — | US | disclosed |
| US-12478680-B2 | Hydrogels with biodegradable crosslinking | PROLYNX LLC (US) | 2025-11-25 | — | — | US | disclosed |
| EP-4025592-B1 | CONJUGATED HEPCIDIN MIMETICS FOR USE IN TREATING OF POLYCYTHEMIA VERA | PROTAGONIST THERAPEUTICS INC (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20030013656-A1 | Pyruvate derivatives | ALLOY VENTURES, INC. | 2003-01-16 | — | — | US | disclosed |
| US-20030013846-A1 | Pyruvate derivatives | ALLOY VENTURES, INC. | 2003-01-16 | — | — | US | disclosed |
| US-20030013847-A1 | Cytoprotective agents | MONSANTO TECHNOLOGY LLC | 2003-01-16 | — | — | US | disclosed |
| US-20030013657-A1 | Pyruvate derivatives | MONSANTO TECHNOLOGY, LLC. | 2003-01-16 | — | — | US | disclosed |
| WO-2002050099-A2 | PROCESS FOR FOLDING CHEMICALLY SYNTHESIZED POLYPEPTIDES | RMF DICTAGENE S.A. (CH) | 2002-06-27 | — | — | WO | disclosed |
| US-20020082384-A1 | Process for folding chemically synthesized polypeptides | RMF DICTAGENE S.A. (CH) | 2002-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013847-A1 | Cytoprotective agents | PC, PDK1, PDK2 | KIF11 3898/4885NOS2 2542/4885NOS1 2886/4885 |
| US-20030013657-A1 | Pyruvate derivatives | PC, PDK1, PDK4 | KIF11 2936/4885NOS2 2879/4885NOS1 3082/4885 |
| US-20030013846-A1 | Pyruvate derivatives | PC, PDK1, PDK4 | KIF11 2936/4885NOS2 2879/4885NOS1 3082/4885 |
| US-20250360187-A1 | HEPCIDIN MIMETICS FOR TREATMENT OF SICKLE CELL DISEASE | HAMP, HBG1, HBG2 | KIF11 4829/4885NOS2 522/4885NOS1 767/4885 |
| US-12478680-B2 | Hydrogels with biodegradable crosslinking | IDUA, APEH, GUSB | KIF11 3027/4885NOS2 623/4885NOS1 844/4885 |
| US-20030013656-A1 | Pyruvate derivatives | PC, PDK1, PDK4 | KIF11 2936/4885NOS2 2879/4885NOS1 3082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.